RxSight, Inc. revenue by segment RXST

Annual Quarterly

RxSight, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Rxlal at $108.1 million, 80% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021
Revenue	115	134	140	89	49	23
Rxlal	102 -5.5% share 88.9%	108 +12.0% share 80.4%	96 +78.4% share 69.0%	54 +116.7% share 60.7%	25 share 50.9%	—
LDD	7 -75.0% share 6.1%	21 -47.9% share 15.4%	40 +23.7% share 28.4%	32 +42.5% share 36.0%	23 +63.5% share 45.9%	14 share 61.0%
LAL	—	—	—	—	—	8 share 36.1%
Service Warranty Service Contracts And Accessories	6 +7.8% share 5.0%	6 +54.3% share 4.3%	4 +28.7% share 2.7%	3 +89.8% share 3.2%	2 +132.5% share 3.1%	1 share 2.9%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Ophthalmic Goods (SIC 3851)
Listed as: RXST (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Aliso Viejo, CA
SEC filer status: Accelerated filer
SEC CIK: 1111485
Former names: CALHOUN VISION INC (until Mar 20, 2014)

Other Ophthalmic Goods companies

All 8 Ophthalmic Goods companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.